Biomarkers of Metabolic (Dysfunction)-associated Fatty Liver Disease: An Update
Open Access
- 13 October 2021
- journal article
- review article
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 10 (1), 134-139
- https://doi.org/10.14218/jcth.2021.00248
Abstract
The prevalence of metabolic (dysfunction)-associated fatty liver disease (MAFLD) is rapidly increasing and affects up to two billion individuals globally, and this has also resulted in increased risks for cirrhosis, hepatocellular carcinoma, and liver transplants. In addition, it has also been linked to extrahepatic consequences, such as cardiovascular disease, diabetes, and various types of cancers. However, only a small proportion of patients with MAFLD develop these complications. Therefore, the identification of high-risk patients is paramount. Liver fibrosis is the major determinant in developing these complications. Although, liver biopsy is still considered the gold standard for the assessment of patients with MAFLD. Because of its invasive nature, among many other limitations, the search for noninvasive biomarkers for MAFLD remains an area of intensive research. In this review, we provide an update on the current and future biomarkers of MAFLD, including a discussion of the associated genetics, epigenetics, microbiota, and metabolomics. We also touch on the next wave of multiomic-based biomarkers.Keywords
This publication has 68 references indexed in Scilit:
- The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non‐alcoholic fatty liver diseaseLiver International, 2016
- Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver diseaseGut, 2016
- Genetic and epigenetic mechanisms of NASHHepatology International, 2015
- FibroGENE: A gene-based model for staging liver fibrosisJournal of Hepatology, 2015
- Meta-analysis of the heritability of human traits based on fifty years of twin studiesNature Genetics, 2015
- Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver diseaseNature Communications, 2015
- OxNASH Score Correlates with Histologic Features and Severity of Nonalcoholic Fatty Liver DiseaseDigestive Diseases and Sciences, 2014
- Absolute quantification by droplet digital PCR versus analog real-time PCRNature Methods, 2013
- Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitisJournal of Lipid Research, 2010
- Risk of Cancer in Patients Hospitalized With Fatty LiverJournal of Clinical Gastroenterology, 2003